Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force

Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T
Record ID 32015001086
English
Authors' objectives: We conducted this review, alongside two companion reviews, to support the U.S. Preventive Services Task Force (USPSTF) in making evidence-based recommendations about the use of aspirin (ASA) for primary prevention in adults and to understand the risks of regular ASA use.
Authors' recommendations: Low-dose ASA use may eventually be shown to provide modest cancer mortality benefits in CVD primary prevention populations, but effects are not clearly established since current estimates are imprecise and relatively unstable. Modest reductions in all-cause mortality effect are more stable, but cannot be completely explained through cancer and/or CVD mortality reduction. Rates of serious bleeding, with and without ASA, are higher than previously suggested in clinical trial populations, and are very important when assessing the likely net benefit of low-dose ASA use as a chemopreventive agent in a more individualized or subpopulation-specific manner.
Details
Project Status: Completed
URL for project: http://www.ncbi.nlm.nih.gov/books/NBK321643/
Year Published: 2015
URL for published report: http://www.ncbi.nlm.nih.gov/books/NBK321643/pdf/Bookshelf_NBK321643.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Humans
  • Adult
  • Aspirin
  • Neoplasms
  • Mortality
Contact
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.